Management and Treatment Goals in Hypercortisolism

In ‘Management and Treatment Goals in Hypercortisolism,’ our panel explores practical approaches to managing patients with hypercortisolism-associated hypertension following diagnosis and discusses the importance of addressing the underlying cause of disease. Expert cardiology faculty examine the role of cardiologists in identifying patients with hypercortisolism and emphasize the value of collaboration with endocrinology colleagues to confirm the diagnosis, determine the underlying etiology, and guide treatment decisions.

The panel discusses treatment goals for patients with hypercortisolism and resistant hypertension, highlighting the importance of moving beyond symptom management and focusing on the root cause of cortisol excess. They explore how identification of underlying hypercortisolism may open opportunities for targeted interventions, including surgical management in appropriate patients and medical therapies for those who are not candidates for surgery.

Throughout the discussion, the expert faculty consider how cardiologists can support ongoing blood pressure management while patients undergo evaluation and treatment for hypercortisolism. They review the rationale for selecting antihypertensive therapies that address pathways affected by cortisol excess and discuss how targeted treatment may help reduce medication burden and improve blood pressure control over time.

The panelists also reflect on the challenges associated with resistant hypertension and emphasize that persistent elevations in blood pressure may not always be explained by medication adherence alone. By recognizing hypercortisolism as a potential driver of treatment-resistant disease, clinicians may be better positioned to identify patients who require further evaluation and more individualized care. The discussion highlights the importance of diagnosis, referral, and targeted treatment as key steps toward improving long-term cardiovascular outcomes.

Our next episode, ‘Emerging Therapies for Hypercortisolism,’ explores the evolving treatment landscape for hypercortisolism and highlights ongoing research into more selective therapeutic approaches. The panelists discuss how emerging therapies and future clinical trials may help improve outcomes for patients with resistant hypertension, diabetes, and other cardiometabolic complications.